SUSTAINED 2-YEAR REMISSION OF THE DISEASE IN A CLINIC OF EXCELLENCE IN RHEUMATOID ARTHRITIS. EXPERIENCE OF THE CLINICAL REGISTRY IN COLOMBIA

被引：0
作者：
Bello-Gualtero, J. M. [1 ,2 ]
Pena, E. [3 ]
Moreno, P. I. Santos [4 ]
Gualdron, J. Vesga [3 ]
Saavedra, G. [5 ]
Perez, C. [6 ]
机构：
[1] Hosp Mil Cent, Rheumatol & Immunol, Bogota, Colombia
[2] Univ Mil Nueva Granada, Grp Inmunol Clin Aplicada, Bogota, Colombia
[3] Pontificia Univ Javeriana, Hlth Econ, Bogota, Colombia
[4] BIOMAB IPS, Rheumatol, Bogota, Colombia
[5] Hosp Mil Cent, Epidemiol, Bogota, Colombia
[6] Hosp Mil Cent, Cuenta Alto Costo, Bogota, Colombia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.3886
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0501
引用
收藏
页码：483 / 483
页数：1
相关论文
共 50 条
  • [31] Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial
    Keystone, Edward C.
    Combe, Bernard
    Smolen, Josef
    Strand, Vibeke
    Goel, Niti
    van Vollenhoven, Ronald
    Mease, Philip
    Landewe, Robert
    Fleischmann, Roy
    Luijtens, Kristel
    van der Heijde, Desiree
    RHEUMATOLOGY, 2012, 51 (09) : 1628 - 1638
  • [32] Sustained minimal disease activity with initial combination treatment in early rheumatoid arthritis.: The 11-year results of the FIN-RACo study
    Rantalaiho, Vappu
    Kautiainen, Hannu
    Jarvenpaa, Salme
    Korpela, Markku
    Hannonen, Pekka
    Leirisalo-Repo, Marjatta
    Hakala, Markku
    Mottonen, Timo
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 37 - 37
  • [33] SUSTAINED EFFECTIVENESS OF METHOTREXATE WITH STEP-DOWN GLUCOCORTICOID REMISSION INDUCTION (COBRA SLIM) FOR EARLY RHEUMATOID ARTHRITIS IN A TREAT-TO- TARGET SETTING: 2-YEAR RESULTS OF THE CARERA TRIAL
    Stouten, V.
    Joly, J.
    De Cock, D.
    Pazmino, S.
    Van der Elst, K.
    Westhovens, R.
    Verschueren, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 147 - 147
  • [34] FIVE-YEAR FOLLOW-UP OF A 2-YEAR MRI TREAT-TOTARGET STRATEGY ON RADIOGRAPHIC DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION - THE IMAGINEMORE STUDY
    Moller-Bisgaard, S.
    Horslev-Petersen, K.
    Ornbjerg, L. Midtboll
    Ejbjerg, B.
    Hetland, M. L.
    Moller, J. Mollenbach
    Christensen, R.
    Nielsen, S. M.
    Glinatsi, D.
    Boesen, M.
    Stengaard-Pedersen, K.
    Madsen, O.
    Jensen, B.
    Villadsen, J. A.
    Hauge, E. M.
    Hendricks, O.
    Lindegaard, H. M.
    Krogh, N. Steen
    Jurik, A. G.
    Thomsen, H.
    Ostergaard, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 235 - 236
  • [35] COMPARING ABATACEPT TO ADALIMUMAB, ETANERCEPT AND INFLIXIMAB AS FIRST OR SECOND LINE AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS. EXPERIENCE FROM THE RHUMADATA® CLINICAL DATABASE AND REGISTRY
    Fortin, I.
    Choquette, D.
    Bessette, L.
    Haraoui, B.
    Pelletier, J. -P.
    Raynauld, J. P.
    Remillard, M-A
    Sauvageau, D.
    Villeneuve, E.
    Coupal, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 273 - 274
  • [36] Comparing Abatacept to Adalimumab, Etanercept and Infliximab as First or Second Line Agents in Patients with Rheumatoid Arthritis. Experience from the RHUMADATA® Clinical Database and Registry
    Coupal, Louis
    Haraoui, Boulos
    Bessette, Louis
    Raynauld, Jean-Pierre
    Pelletier, Jean-Pierre
    Massicotte, Frederic
    Remillard, Marie-Anais
    Sauvageau, Diane
    Villeneuve, Edith
    Choquette, Denis
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1314 - 1314
  • [37] Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry.
    Choquette, Denis
    Bessette, Louis
    Fortin, Isabelle
    Haraoui, Boulos
    Pelletier, Jean Pierre
    Raynauld, Jean-Pierre
    Remillard, Marie-Anais
    Sauvageau, Diane
    Villeneuve, Edith
    Coupal, Louis
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S676 - S677
  • [38] Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis
    Yamasaki, Masaomi
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [39] D-penicillamine in early rheumatoid arthritis: Experience from a 2-year double blind placebo controlled study
    Eberhardt, K
    Rydgren, L
    Fex, E
    Svensson, B
    Wollheim, FA
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1996, 14 (06) : 625 - 631
  • [40] The disease course of patients with rheumatoid arthritis in remission: A prospective 2 year follow-up study.
    Molenaar, ET
    Voskuyl, AE
    Dinant, HJ
    Bezemer, DP
    Dijkmans, BA
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S277 - S277
12345